A Phase II, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of HEX17, a Novel Broad-Spectrum Antiviral Drug, in a Controlled Human Infection Model of Influenza Challenge

A Phase II, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of HEX17, a Novel Broad-Spectrum Antiviral Drug, in a Controlled Human Infection Model of Influenza Challenge

Abstract Introduction Viral respiratory tract infections are of global concern, with an unmet need for a broad-spectrum antiviral prophylactic. HEX17, a multivalent carbohydrate-binding module, binds to sialic acid, a cell surface glycan used by many viruses for host cell entry. HEX17 represents a p...

Full description

Saved in:
Bibliographic Details
Main Authors: Geoff Kitson, Marion Byford, Lindsey Cass, David Howat, Brigitte Köhn, Alessandra Bisquera, Andrew Catchpole, Nicolas Noulin, Douglas Thomson
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-07-01
Series:Infectious Diseases and Therapy
Subjects:
Antiviral prophylactic therapy
HEX17
Influenza
Neumifil
Randomised controlled trial
Respiratory tract infection
Online Access:https://doi.org/10.1007/s40121-025-01179-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40121-025-01179-2

Similar Items